(VIANEWS) – The NYSE opens in less than one hour and Catalent‘s pre-market value is already 4.65% down.
Catalent’s last close was $71.37, 38.12% below its 52-week high of $115.33.
The last session, NYSE finished with Catalent (CTLT) falling 0.72% to $71.37. NYSE dropped 0.21% to $15,840.16, after four consecutive sessions in a row of losses, on what was a somewhat down trend exchanging session.
About Catalent
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Earnings Per Share
As for profitability, Catalent has a trailing twelve months EPS of $1.8.
PE Ratio
Catalent has a trailing twelve months price to earnings ratio of 39.54. Meaning, the purchaser of the share is investing $39.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.73%.
Yearly Top and Bottom Value
Catalent’s stock is valued at $71.37 at 08:42 EST, way under its 52-week high of $115.33 and way above its 52-week low of $40.69.
Sales Growth
Catalent’s sales growth is negative 9.9% for the present quarter and 5.9% for the next.
More news about Catalent (CTLT).
